Redhill Biopharma (STU:2RH) Short Interest


STU:2RH Redhill Biopharma Ltd STU:2RH
18 GF Score
Price €8.24
! 6 Warning Signs
View Full Analysis

What is Redhill Biopharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:2RH vs LVRLF, BUDZ, GELS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redhill Biopharma Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Short Interest distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Short Interest falls into.


STU:2RH
18GF Score
Redhill Biopharma Ltd STU:2RH
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Redhill Biopharma Business Description

Other Exchanges RDHL:USA
Address 21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score

Get the complete analysis for STU:2RH

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.24
Price